Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Lipocine stock opened at $3.54 on Friday. The firm has a market capitalization of $18.94 million, a price-to-earnings ratio of -4.66 and a beta of 1.42. Lipocine has a fifty-two week low of $2.91 and a fifty-two week high of $11.79. The stock’s fifty day moving average is $3.79 and its two-hundred day moving average is $4.53.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC lifted its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the period. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.